Hydralazine-Induced Vasculitis: Case Insights and Literature Review for Informed Clinical Recognition and Management.
Cureus
; 15(12): e50338, 2023 Dec.
Article
en En
| MEDLINE
| ID: mdl-38205473
ABSTRACT
Hydralazine, a commonly prescribed medication for hypertension, has been associated, albeit rarely, with the development of vasculitis. The case presentation involves a 51-year-old female with diabetes and hypertension who presented with a distinctive rash, pancytopenia, and positive findings for various antibodies. A collaborative approach involving rheumatology, hematology, and dermatology was crucial in diagnosing leukocytoclastic vasculitis attributed to hydralazine. Prompt discontinuation of hydralazine and the initiation of a tailored treatment plan led to favorable outcomes. The study sheds light on the clinical manifestations, diagnostic challenges, and management strategies associated with this rare side effect, providing valuable insights for healthcare providers. Increased awareness of hydralazine-induced vasculitis is crucial for early recognition and proper management, ultimately contributing to improved patient outcomes in hypertension management.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
Cureus
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos
Pais de publicación:
Estados Unidos